Systemic Juvenile Idiopathic Arthritis Clinical Trial
Official title:
Changes in Joint-Cartilage as a Measure of Outcome in Juvenile Idiopathic Arthritis - Assessed by Ultrasonography and Biomarkers
The purpose of this study is to analyse the usability of ultrasonography together with biomarkers in the investigation of patients diagnosed with juvenile idiopathic arthritis. The investigators hypothesize that serum and urine markers of cartilage and bone synthesis and degradation, together with ultrasound measurements of joint cartilage thickness, are useful tools in the early evaluation of JIA patients, - as diagnostic, prognostic and monitoring methods.
n/a
Observational Model: Cohort, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00891046 -
An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.
|
Phase 3 | |
| Completed |
NCT02334748 -
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
|
Phase 3 | |
| Completed |
NCT01803321 -
Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
|
Phase 1 | |
| Completed |
NCT00144664 -
Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
|
Phase 3 | |
| Completed |
NCT02396212 -
Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA
|
Phase 3 | |
| Completed |
NCT00144599 -
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 3 | |
| Terminated |
NCT00886769 -
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
|
Phase 3 | |
| Completed |
NCT00144612 -
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 3 | |
| Withdrawn |
NCT01676948 -
An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
|
Phase 3 | |
| Recruiting |
NCT04088396 -
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 3 | |
| Recruiting |
NCT05027373 -
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection
|
Phase 1 |